

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarci⦠read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
$2.66
Price-5.78%
-$0.16
$11.562m
Small
-
Premium
Premium
-471.7%
EBITDA Margin-541.1%
Net Profit Margin-479.3%
Free Cash Flow Margin-471.7%
EBITDA Margin-541.1%
Net Profit Margin-479.3%
Free Cash Flow Margin$1.403m
+18.0%
1y CAGR+141.7%
3y CAGR+106.3%
5y CAGR-$8.892m
-650.8%
1y CAGR-159.6%
3y CAGR-155.4%
5y CAGR-$2.12
-631.0%
1y CAGR-149.8%
3y CAGR-136.2%
5y CAGR$20.835m
$38.797m
Assets$17.962m
Liabilities$9.070m
Debt23.4%
-1.1x
Debt to EBITDA-$7.823m
+4.2%
1y CAGR-2.1%
3y CAGR+1.9%
5y CAGR